Table 4.

Treatment of Manifestations in Individuals with LMNA-related DCM

Manifestation/ConcernTreatment
Cardiac conduction
system disease &
arrhythmias
For chronic atrial fibrillation unresponsive to cardioversion:
  • Anticoagulants
  • Agents for ventricular rate control
For other symptomatic supraventricular arrhythmias:
  • Pharmacologic agents
  • May be augmented with electrophysiologic intervention (e.g., atrial or atrioventricular node ablations)
For symptomatic bradyarrhythmias or asymptomatic but significant heart block:
  • An implantable electronic pacemaker
  • Strongly consider an ICD (not an electronic pacemaker) due to risk of mortality from sudden cardiac death.
For symptomatic ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, & resuscitated sudden cardiac death:
  • Use of an ICD
  • Drug therapy as needed
Dilated
cardiomyopathy
ACE inhibitors, beta blockers, diuretics, & other conventional approaches, as summarized in Yancy et al [2013] (full text)
When DCM is present & left ventricular ejection fraction is <35% (w/or w/o arrhythmia): use of an ICD
For progressive deterioration in left ventricular function despite full medical & device therapy, consider:
  • Cardiac transplantation;
  • Durable mechanical circulatory support if cardiac transplantation is contraindicated.

ICD = implantable cardioverter defibrillator

From: LMNA-Related Dilated Cardiomyopathy

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.